Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib
Phase 3
Completed
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2017-02-17
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 80
- Registration Number
- NCT01910987
A Study to Compare the Pharmacodynamics of Canagliflozin and Dapagliflozin in Healthy Volunteers
- First Posted Date
- 2013-06-14
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 60
- Registration Number
- NCT01877889
A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection
Phase 3
Completed
- Conditions
- Hepatitis C, ChronicInfection
- Interventions
- First Posted Date
- 2013-05-03
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 232
- Registration Number
- NCT01846832
A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy Compared With Placebo
Phase 3
Completed
- Conditions
- Hallux Valgus
- Interventions
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2015-01-09
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 60
- Registration Number
- NCT01813890
A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-11-22
- Last Posted Date
- 2013-09-10
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 18
- Registration Number
- NCT01732237
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
Phase 3
Completed
- Conditions
- Human Immunodeficiency Virus-type 1 Infection
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 426
- Registration Number
- NCT01709084
Effects of Canagliflozin on C-peptide Clearance in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2012-08-15
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 10
- Registration Number
- NCT01665638
A Single Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-42165279 in Healthy Male Participants
Phase 1
Completed
- Conditions
- Healthy VolunteersPharmacokinetics
- Interventions
- First Posted Date
- 2012-07-26
- Last Posted Date
- 2017-07-06
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 29
- Registration Number
- NCT01650597
Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease.
Completed
- Conditions
- Esophageal RefluxGERDGastroesophageal Reflux DiseaseGastro-oesophageal RefluxGastro-Esophageal Reflux
- First Posted Date
- 2012-05-18
- Last Posted Date
- 2016-05-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 7964
- Registration Number
- NCT01601379
An Efficacy and Safety Study of Telaprevir in Patients With Genotype 1 Hepatitis C Infection After Liver Transplantation
Phase 3
Completed
- Conditions
- Chronic Hepatitis C Virus (HCV) Infection
- Interventions
- First Posted Date
- 2012-04-05
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 74
- Registration Number
- NCT01571583
© Copyright 2025. All Rights Reserved by MedPath